Register Login

Fulcrum Therapeutics (FULC)

(90% Positive) Fulcrum Therapeutics, Inc. (FULC) Announces Enrollment Update for complete Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 29, 2025, 11:08 a.m.

    📋 Fulcrum Therapeutics, Inc. (FULC) - Clinical Trial Update

    Filing Date: 2025-10-29

    Accepted: 2025-10-29 07:05:27

    Event Type: Clinical Trial Update

    Event Details:

    Fulcrum Therapeutics (FULC) Announces Clinical Trial Update Fulcrum Therapeutics (FULC) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: complete, outcomes
    • Collaboration: the Phase 1b PIONEER
    • Updated Timeline: October 29, 2025, the end of 2025
      • end ― ― Ended Q3 2025 with $
      • 6 million in cash, cash equivalents, and marketable securities; cash runway into 2028 ― CAMBRIDGE, Mass., – October 29, 2025 – Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical
      • stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the third quarter of 2025 and provided a business update. “We are extremely pleased with the compelling data from the 12 mg dose cohort of the PIONEER trial, which demonstrated that pociredir has the potential to meaningfully improve outcomes for people living with sickle cell disease,” said Alex C. Sapir, Fulcrum’s President and Chief Executive Officer. “The strength of those results has generated significant interest and engagement from investigators and patients, reflected in the over

    🔬 Clinical Development Pipeline (Fulcrum Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Losmapimod DRUG Phase PHASE2 Facioscapulohumeral Muscular Dystrophy (FSHD) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Fulcrum Therapeutics
    • CIK: 0001680581
    • Ticker Symbol: FULC
    • Period End Date: 2025-10-29
    • Document Type: 8-K

Search

News categories